IL-10 Biomarker Stratification for SLE Treatment Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Systemic Lupus Erythematosus (SLE) face challenges due to limited efficacy and adverse effects of standard therapies, with a lack of reliable biomarkers for predicting patient response to treatment, leading to failed clinical trials and ongoing need for targeted therapies that reduce corticosteroid use.
Innovation Solution
The use of IL-10 plasma concentration as a predictive biomarker to select SLE patients for treatment with type I IFN receptor inhibitors or anti-BAFF monoclonal antibodies, where patients with lower IL-10 levels respond better to IFN inhibitors and those with higher IL-10 levels benefit from anti-BAFF and anti-CD20 antibody combinations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard therapies (corticosteroids and immunosuppressive agents) are used to treat SLE, then disease activity is reduced, but adverse effects and limited efficacy occur
Solution Approach 1:
The patent changes the therapeutic parameter by targeting specific cytokine pathways (Type I IFN and IL-10) rather than using broad immunosuppression. By measuring IL-10 plasma concentration and stratifying patients into high and low groups, the treatment parameter is optimized for each subgroup, improving efficacy while reducing adverse effects from unnecessary broad immunosuppression.
Solution Approach 2:
The patent applies local quality by providing differentiated treatment strategies based on patient-specific IL-10 levels. High IL-10 patients receive anti-BAFF and anti-CD20 therapy, while low IL-10 patients receive IFN inhibitor therapy. This localized approach tailors treatment to individual patient characteristics, improving therapeutic reliability while minimizing harmful effects.
2Reliability
If clinical trials are conducted without predictive biomarkers, then treatment efficacy is evaluated, but patient selection is insufficient leading to trial failures
Solution Approach 1:
The patent performs preliminary action by measuring IL-10 plasma concentration before initiating treatment to stratify patients into high and low groups. This pre-treatment biomarker assessment enables selective assignment to appropriate therapy regimens, improving clinical trial reliability by ensuring patients receive tailored treatments they are most likely to respond to.
Solution Approach 2:
The patent implements feedback by using IL-10 plasma concentration measurements to guide treatment selection. The biomarker information is fed back into the treatment decision-making process, allowing clinicians to adjust therapy based on individual patient characteristics. This feedback mechanism improves trial success rates by aligning treatment strategies with patient-specific disease characteristics.
3Productivity
If heterogeneous patient populations are treated uniformly, then trial enrollment is simplified, but disease heterogeneity causes poor treatment response
Solution Approach 1:
The patent applies segmentation by dividing the heterogeneous SLE patient population into two distinct subgroups based on IL-10 plasma concentration: high IL-10 group and low IL-10 group. This segmentation allows each subgroup to receive optimized treatment strategies, improving treatment response reliability while maintaining manageable trial enrollment through clear stratification criteria.
Data Source
AI summary
The disclosure relates to methods and compositions for the treatment of Systemic Lupus Erythematosus (SLE). Specifically, the disclosure relates to methods comprising administering to a subject a type I IFN receptor inhibitor.